Atazanavir/ritonavir ↓ lamotrigine Decreased lamotrigine AUC approximately 32%.
Source: FDA drug label - lamotrigine extended release
Lamotrigine Extended Release Interactions
Brand names: Lamotrigine Extended Release
Anti-epileptic Agent · Mood Stabilizer · Organic Cation Transporter 2 Inhibitors · Dihydrofolate Reductase Inhibitors
FDA Black Box Warning
WARNING: SERIOUS SKIN RASHES Lamotrigine extended-release can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.8% (8 per 1,000) in pediatric patients (aged 2 to 16 years) receiving immediate-release lamotrigine as adjunctive therapy for epilepsy and 0.3% (3 per 1,000) in adults on adjunctive therapy for epilepsy. In a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking adjunctive immediate-release lamotrigine, there was 1 rash-related death. Lamotrigine extended-release is not approved for patients younger than 13 years. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate. The risk of serious rash caused by treatment with lamotrigine extended-release is not expected to differ from that with immediate-release lamotrigine. However, the relatively limited treatment experience with lamotrigine extended-release makes it difficult to characterize the frequency and risk of serious rashes caused by treatment with lamotrigine extended-release. In addition to age, factors that may increase the risk of occurrence or the severity of rash caused by lamotrigine extended-release include (1) coadministration of lamotrigine extended-release with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of lamotrigine extended-release, (3) exceeding the recommended dose escalation for lamotrigine extended-release, or (4) the presence of the HLA-B*1502 allele. However, cases have occurred in the absence of these factors. Nearly all cases of life-threatening rashes caused by immediate-release lamotrigine have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurr
3 interactions on record
Lopinavir/ritonavir ↓ lamotrigine Decreased lamotrigine concentration approximately 50%.
Source: FDA drug label - lamotrigine extended release
Lopinavir/ritonavir ↓ lamotrigine Decreased lamotrigine concentration approximately 50%. Atazanavir/ritonavir ↓ lamotrigine Decreased lamotrigine AUC approximately 32%.
Source: FDA drug label - lamotrigine extended release